Latest papers

Phase I trial of low dose decitabine targeting DNA hypermethylation in patients with chronic lymphocytic leukaemia and non-Hodgkin lymphoma: dose-limiting myelosuppression without evidence of DNA hypomethylation.

Promoter hypomethylation contributes to the expression of MUC3A in cancer cells.

Downregulation of WIF-1 by hypermethylation in astrocytomas.

Function and regulatory mechanisms of the candidate tumor suppressor receptor protein tyrosine phosphatase gamma (PTPRG) in breast cancer cells.

5-Aza-2'-deoxycytidine is a potent inhibitor of DNA methyltransferase 3B and induces apoptosis in human endometrial cancer cell lines with the up-regulation of hMLH1.

5-Aza-2′-deoxycytidine treatment induces skeletal myogenic differentiation of mouse dental pulp stem cells

Phase 2 clinical trial of 5-azacitidine, valproic acid, and all-trans retinoic acid in patients with high-risk acute myeloid leukemia or myelodysplastic syndrome.

Advances in the management of acute myeloid leukemia in older adult patients.

Altered DNA methylation is associated with docetaxel resistance in human breast cancer cells.

Azacitidine for the treatment of myelodysplastic syndrome, chronic myelomonocytic leukaemia and acute myeloid leukaemia.

[The relationship between the TSLC1 silencing and DNA methylation in human lung cancer cells].

Exposure to cardiomyogenic stimuli fails to transdifferentiate human umbilical cord blood-derived mesenchymal stem cells.

Upregulation of DNA methyltransferase-mediated gene silencing, anchorage-independent growth, and migration of colon cancer cells by interleukin-6.

Porcupine expression is associated with the expression of S100P and other cancer-related molecules in non-small cell lung carcinoma.

[No correlation between the sensitivity to 5-aza-dC and the global DNA methylation level in hepatocellular carcinoma cells].

Predonor lymphocyte infusion treatment with 5-azacytidine as salvage treatment in relapsed acute myeloid leukaemia secondary to myelodysplastic syndrome.

Regulation of Toll-like receptor 4-associated MD-2 in intestinal epithelial cells: a comprehensive analysis.

Reduction of 5-azacitidine induced skin reactions in MDS patients with evening primrose oil.

Efficacy of a 3-day, low-dose treatment with 5-azacytidine followed by donor lymphocyte infusions in older patients with acute myeloid leukemia or chronic myelomonocytic leukemia relapsed after allografting.

Effects of decitabine on the expression of selected endogenous control genes in human breast cancer cells.